plural feet play \ˈfēt\ also foot 2 : an invertebrate organ of locomotion or attachment; especially : a ventral muscular surface or process of a mollusc 3 : any of various units of length based on the length of the human foot; especially : a unit equal to 1⁄3 garden and comprising 12 inches plural foot used between a number and a noun plural feet or foot used between a number and an adjective — see weight table 4 : the basic unit of verse meter consisting of any of various fixed combinations or groups of stressed and unstressed or long and short syllables 5 a : motion or power of walking or running : step b : speed, swiftness 6 : something resembling a foot in position or use: as a : the lower end of the leg of a chair or table b 1 : the basal portion of the sporophyte in mosses 2 : a specialized outgrowth by which the embryonic sporophyte especially of many bryophytes absorbs nourishment from the gametophyte c : a piece on a sewing machine that presses the cloth against the feed 7 foot plural chiefly British : infantry 8 : the lower edge as of a sail 9 : the lowest part : bottom 10 a : the end that is lower or opposite the head b : the part as of a stocking that covers the foot 11 foots plural but sing or plural in constr : material deposited especially in ageing or refining : dregs
T.J. DeSantis, a resident opposed to repeal, argued that it was not necessarily people who live in Hoboken who flood the bars on weekends and disturb the peace late into the night. “Maybe the demographics have changed, but the visitors haven’t changed,” DeSantis said. Michael Galucci, who owns the Green Rock Tap & Grill on Hudson Street, told the council on Monday that his landlord and others are able to demand huge rent increases from bar owners due to the 500-foot rule. “We have nowhere to go,” Galucci said. Juan Melli, a spokesman for Mayor Dawn Zimmer, said the mayor does not have a position on the repeal proposal. you could try this outHoboken Police Chief Kenneth Ferrante said in an interview that he is concerned the repeal make existing trouble spots worse where bars are already clustered from the prior repeal. “This abandonment of the 500-foot rule brings the potential to have more clusters,” Ferrante said. “This is what brings noise. This is what brings fights.” Russo said that repealing the rule would not increase the Mile-Square City’s total of 134 liquor licenses.
For the original version including any supplementary images or video, visit http://www.nj.com/hudson/index.ssf/2016/09/hoboken_reaction_500-foot_rule_bars.html
We are particularly excited by these findings and to understand the internal signaling systems used by Resunab that exhibits such a favorable result in humans,” stated Professor Gilroy. Barbara White, M.D., Chief Medical Officer of the Company, commented, “The results from this study support the intended pharmacological activity of Resunab, which is resolution of chronically activated innate immune responses, including tissue inflammation and fibrosis. We look forward to continued collaborations with Dr. Gilroy and his colleagues, to further define the impact of Resunab on inflammatory responses — especially resolution — in humans.” additional resourcesCorbus is currently developing its novel synthetic oral endocannabinoid-mimetic drug, Resunab , that is designed to resolve chronic inflammation and halt fibrosis. Resunab is currently being evaluated in three separate Phase 2 clinical studies in diffuse cutaneous systemic sclerosis (“systemic sclerosis”), cystic fibrosis (“CF”), diffuse cutaneous, and skin-predominant dermatomyositis . Corbus expects to report top-line data from its Phase 2 clinical study in systemic sclerosis in the fourth quarter of 2016. Corbus recently announced that it has completed subject enrollment in its Phase 2 clinical study of Resunab for the treatment of CF and the Company expects to report top-line results from this study early in the first quarter of 2017. The Company expects to complete enrollment and report top line results from the dermatomyositis study in the second half of 2017. A fourth NIH-sponsored clinical study of Resunab in systemic lupus erythematosus (“SLE”) is planned to begin during the first half of 2017. Read More About Resunab Resunab is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/corbus-announces-data-effects-resunab-113000938.html